What this is
- How it works
- How it works isn't classified yet
- Tested for
- Neoplasms, Hematologic
- Main trialPhase 2
- “The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.”In the company’s words, NCT01594723 on ClinicalTrials.gov
Other drugs for Neoplasms, Hematologic
- Givinostat HydrochlorideItalfarmaco · Phase 3
- QTX-2101Quetzal Therapeutics · Phase 3
- RusfertideProtagonist Therapeutics, Inc. · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- PelabresibNovartis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 20 Mar 2015 | A Study of LY2784544 in Participants With Myeloproliferative Neoplasms |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026